Literature DB >> 24796269

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Valeria Visconte1, Ali Tabarroki, Li Zhang, Edy Hasrouni, Chris Gerace, Robyn Frum, Jing Ai, Anjali S Advani, Hien K Duong, Matt Kalaycio, Yogen Saunthararajah, Mikkael A Sekeres, Eric D His, Shashirekha Shetty, Heesun J Rogers, Ramon V Tiu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24796269     DOI： 10.1002/ajh.23755

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  7 in total

1.  The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.

Authors:  M Meggendorfer; C Haferlach; M Zenger; K Macijewski; W Kern; T Haferlach
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

Review 2.  Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Authors:  Valeria Visconte; Ramon V Tiu; Heesun J Rogers
Journal:  Blood Res       Date:  2014-12-23

3.  Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity.

Authors:  Eleftheria Lamprianidou; Chryssoula Kordella; Menelaos Papoutselis; Zoi Bezyrgiannidou; Evangelia Nakou; Spyros Papamichos; Emmanouil Spanoudakis; Andreas Giannopoulos; Katerina Zoi; Ioannis Kotsianidis
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-11-01       Impact factor: 2.576

4.  Prognostic significance of isochromosome 17q in hematologic malignancies.

Authors:  Dorota Koczkodaj; Justyna Muzyka-Kasietczuk; Sylwia Chocholska; Monika Podhorecka
Journal:  Oncotarget       Date:  2021-03-30

5.  Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.

Authors:  Rashmi Kanagal-Shamanna; Attilio Orazi; Robert P Hasserjian; Daniel A Arber; Kaaren Reichard; Eric D Hsi; Adam Bagg; Heesun Joyce Rogers; Julia Geyer; Faezeh Darbaniyan; Kim-Anh Do; Kyle M Devins; Olga Pozdnyakova; Tracy I George; Paola Dal Cin; Patricia T Greipp; Mark J Routbort; Keyur Patel; Guillermo Garcia-Manero; Srdan Verstovsek; L Jeffrey Medeiros; Sa A Wang; Carlos Bueso-Ramos
Journal:  Mod Pathol       Date:  2021-11-13       Impact factor: 7.842

6.  Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.

Authors:  Rashmi Kanagal-Shamanna; Rajyalakshmi Luthra; Cameron C Yin; Keyur P Patel; Koichi Takahashi; Xinyan Lu; John Lee; Chong Zhao; Francesco Stingo; Zhuang Zuo; Mark J Routbort; Rajesh R Singh; Patricia Fox; Farhad Ravandi; Guillermo Garcia-Manero; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Oncotarget       Date:  2016-03-22

Review 7.  SETBP1 dysregulation in congenital disorders and myeloid neoplasms.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Antonella Zagaria; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2017-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.